

SEARCH HISTORY

=&gt; d his nofile

(FILE 'HOME' ENTERED AT 14:13:58 ON 22 MAR 2007)

FILE 'HCAPLUS' ENTERED AT 14:14:49 ON 22 MAR 2007

E OTTINGER I/AU  
 L1 5 SEA ABB=ON PLU=ON OTTINGER ISABEL/AU  
 D SCAN  
 L2 QUE ABB=ON PLU=ON OTTINGER I?/AU  
 L3 QUE ABB=ON PLU=ON NOVARTIS?/PA,CS,SO,CO  
 L4 5 SEA ABB=ON PLU=ON L2 AND L3  
 L5 5 SEA ABB=ON PLU=ON L4 AND L1  
 E RENIN/CT  
 L6 4174 SEA ABB=ON PLU=ON RENIN(3A)INHIBIT?  
 L7 2 SEA ABB=ON PLU=ON L5 AND L6  
 D 1-2 ALL  
 SEL L7 RN

FILE 'REGISTRY' ENTERED AT 14:21:45 ON 22 MAR 2007

L8 23 SEA ABB=ON PLU=ON (173334-57-1/BI OR 173334-58-2/BI  
 OR 9015-94-5/BI OR 105-34-0/BI OR 121584-18-7/BI OR  
 124-07-2/BI OR 16170-82-4/BI OR 222414-51-9/BI OR  
 25322-68-3/BI OR 26402-26-6/BI OR 31565-12-5/BI OR  
 538-23-8/BI OR 53824-77-4/BI OR 61909-81-7/BI OR  
 621-71-6/BI OR 7384-98-7/BI OR 875271-36-6/BI OR  
 875271-37-7/BI OR 875271-38-8/BI OR 875271-39-9/BI OR  
 9000-83-3/BI OR 9002-96-4/BI OR 9005-65-6/BI)  
 D SCAN

FILE 'REGISTRY' ENTERED AT 14:26:28 ON 22 MAR 2007

L9 2 SEA ABB=ON PLU=ON L8 AND 1/NR AND 3/N  
 D SCAN  
 L10 21 SEA ABB=ON PLU=ON L8 NOT L9  
 L11 1 SEA ABB=ON PLU=ON L10 AND 2/NC  
 D SCAN  
 L12 20 SEA ABB=ON PLU=ON L10 NOT L11  
 D SCAN  
 L13 1 SEA ABB=ON PLU=ON L12 AND NC>1  
 D SCAN  
 L14 19 SEA ABB=ON PLU=ON L12 NOT L13  
 D SCAN  
 E C30 H53 N3 O6/MF  
 L15 55 SEA ABB=ON PLU=ON C30H53N3O6?/MF  
 D SCAN  
 L16 4 SEA ABB=ON PLU=ON L9 OR L11 OR L13  
 D SCAN  
 D 1-4 RN STR  
 D 1-4 CRN STR

FILE 'LREGISTRY' ENTERED AT 14:44:36 ON 22 MAR 2007

L17 STR 173334-57-1

FILE 'REGISTRY' ENTERED AT 15:12:28 ON 22 MAR 2007

L18 1 SEA SSS SAM L17  
 D SCAN  
 L19 22 SEA SSS FUL L17  
 SAV L19 POR258REG/A  
 L20 4 SEA ABB=ON PLU=ON L8 AND L19  
 D SCAN  
 L21 0 SEA ABB=ON PLU=ON L19 AND MEDLINE/LC  
 L22 3 SEA ABB=ON PLU=ON L19 AND EMBASE/LC  
 D SCAN  
 L23 1 SEA ABB=ON PLU=ON L19 AND BIOSIS/LC  
 D SCAN

10/580258

FILE 'HCAPLUS' ENTERED AT 15:16:04 ON 22 MAR 2007

L24 87 SEA ABB=ON PLU=ON L20  
L25 88 SEA ABB=ON PLU=ON L19  
L26 69 SEA ABB=ON PLU=ON L6 AND L25  
E RENIN/CT  
L27 QUE ABB=ON PLU=ON INHIBIT? OR HINDER? OR IMPED? OR  
ARREST? OR REDUC? OR REDN# OR RESIST? OR SUPPRESS? OR  
RETARD? OR PROHIBIT? OR PREVENT? OR BLOCK? OR ELIMINAT?  
OR LESS? OR ABAT? OR DEPRESS? OR DIMINISH? OR  
CURTAIL? OR ABSEN? OR REMOV? OR RETARD?  
L28 6903 SEA ABB=ON PLU=ON RENIN(3A)L27  
L29 69 SEA ABB=ON PLU=ON L25 AND L28  
L30 QUE ABB=ON PLU=ON PHARMAC?/SC,SX  
L31 QUE ABB=ON PLU=ON PY<2005 OR PRY<2005 OR AY<2005 OR  
MY<2005 OR REVIEW/DT  
L32 48 SEA ABB=ON PLU=ON L29 AND L31  
L33 42 SEA ABB=ON PLU=ON L32 AND L30

FILE 'STNGUIDE' ENTERED AT 15:28:11 ON 22 MAR 2007

FILE 'ZCAPLUS' ENTERED AT 15:29:36 ON 22 MAR 2007  
E HBL SURFACTANT/CT

FILE 'STNGUIDE' ENTERED AT 15:35:43 ON 22 MAR 2007

FILE 'HCAPLUS' ENTERED AT 15:41:14 ON 22 MAR 2007

FILE 'ZCAPLUS' ENTERED AT 15:41:26 ON 22 MAR 2007

L34 QUE ABB=ON PLU=ON HYDROPHIL? OR LIPOPHIL? OR  
SURFACTANT? OR HLB

FILE 'HCAPLUS' ENTERED AT 15:42:10 ON 22 MAR 2007

L35 3 SEA ABB=ON PLU=ON L33 AND L34  
D SCAN  
D 1-3 AU

FILE 'STNGUIDE' ENTERED AT 15:44:01 ON 22 MAR 2007

L36 QUE ABB=ON PLU=ON MICROEMULSION? OR FATTY(A)ACID OR  
TRIGLYCERID? OR WATER(W)IN(W)OIL OR STEARAT?

FILE 'HCAPLUS' ENTERED AT 15:48:35 ON 22 MAR 2007

D IS  
L37 8 SEA ABB=ON PLU=ON L33 AND L36  
L38 10 SEA ABB=ON PLU=ON L35 OR L37

FILE 'REGISTRY' ENTERED AT 15:49:34 ON 22 MAR 2007

D SCAN L14  
L39 11 SEA ABB=ON PLU=ON L14 AND C>7  
D SCAN  
L40 8 SEA ABB=ON PLU=ON L14 NOT L39  
D SCAN  
L41 2 SEA ABB=ON PLU=ON L40 AND PMS/CI  
D SCAN  
L42 13 SEA ABB=ON PLU=ON L39 OR L41  
L43 6 SEA ABB=ON PLU=ON L40 NOT L41  
D SCAN  
L44 3 SEA ABB=ON PLU=ON L43 AND 1-5/N  
D SCAN

FILE 'HCAPLUS' ENTERED AT 15:56:04 ON 22 MAR 2007

L45 QUE ABB=ON PLU=ON L42  
L46 QUE ABB=ON PLU=ON L44  
L47 3 SEA ABB=ON PLU=ON L33 AND L45  
L48 1 SEA ABB=ON PLU=ON L33 AND L46  
D SCAN  
L49 QUE ABB=ON PLU=ON (FATTY# OR LONGCHAIN? OR LONG##(W)C  
HAIN## OR ALIPHATIC? OR ALIPH# OR ALKANOIC?) (2A)ACID#

L50 QUE ABB=ON PLU=ON (HEXANOIC# OR CAPROIC# OR HEPTANOIC  
# OR ENANTHIC# OR OCTANOIC# OR CAPRYLIC#) (2A)ACID#

L51 QUE ABB=ON PLU=ON (NONANOIC# OR PELARGONIC# OR  
DECANOIC# OR CAPRIC# OR OBTUSILIC# OR CAPROLEIC#) (2A)AC  
ID#

L52 QUE ABB=ON PLU=ON (UNDECANOIC# OR DODECANOIC# OR  
LAURIC# OR LAUROLEIC# OR TRIDECANOIC# OR TETRADECANOIC#  
) (2A)ACID#

L53 QUE ABB=ON PLU=ON (MYRISTIC# OR MYRISTOLEIC# OR  
PENTADECANOIC# OR HEXADECANOIC# OR PALMITIC#) (2A)ACID#

L54 QUE ABB=ON PLU=ON (PALMITOLEIC# OR HEPTADECANOIC# OR  
MARGARIC# OR DATURIC# OR OCTADECANOIC#) (2A)ACID#

L55 QUE ABB=ON PLU=ON (STEARIC# OR OLEIC OR PETROSELINIC#  
OR VACCENIC# OR NONADECANOIC#) (2A)ACID#

L56 QUE ABB=ON PLU=ON (EICOSANIC# OR ARACHIDIC# OR  
GADOLEIC# OR HENEISANOIC# OR DOCOSANIC# OR BEHENIC#) (2  
A)ACID#

L57 QUE ABB=ON PLU=ON (CETOLEIC# OR ERUCIC# OR TRICOSANOI  
C# OR TETRACOSANIC# OR LIGNOCERIC# OR SELACHOLEIC#) (2A  
)ACID#

L58 QUE ABB=ON PLU=ON (PENTACOSANOIC# OR HEXACOSANIC#  
OR CEROTIC# OR HEPTACOSANOIC#) (2A)ACID#

L59 QUE ABB=ON PLU=ON (OCTACOSANOIC# OR MONTANIC# OR  
NONACOSANOIC# OR TRIACONTANOIC#) (2A)ACID#

L60 QUE ABB=ON PLU=ON (MELISSIC# OR DOTRIACONTANOIC# OR  
LACCEROIC# OR TRITRIACONTANOIC#) (2A)ACID#

L61 QUE ABB=ON PLU=ON (TETRATRIACONTANOIC# OR PENTATRIACO  
NTANOIC# OR HEXATRIACONTANOIC#) (2A)ACID#

L62 QUE ABB=ON PLU=ON (HEPTATRIACONTANOIC# OR OCTATRIACON  
TANOIC# OR TALLOW# OR COCO#) (2A)ACID#

L63 QUE ABB=ON PLU=ON (COCONUT# OR LINOLEIC# OR LINOLENIC  
# OR ARACHIDONIC# OR ELAIDIC# OR RICINOLEIC#) (2A)ACID#

L64 QUE ABB=ON PLU=ON EMERSOL# OR HYDROFOL# OR HYSTRENE#  
OR LUNAC OR PRIOLENE#

L65 7 SEA ABB=ON PLU=ON L33 AND ((L49 OR L50 OR L51 OR L52  
OR L53 OR L54 OR L55 OR L56 OR L57 OR L58 OR L59 OR  
L60 OR L61 OR L62 OR L63 OR L64))

L66 12 SEA ABB=ON PLU=ON L35 OR (L37 OR L38) OR (L47 OR  
L48) OR L65  
SAV L66 POR258HCP/A  
D SCAN L66  
D QUE L33

L67 30 SEA ABB=ON PLU=ON L33 NOT L66  
SAV L67 POR258HCPA/A  
SAV L5 POR258HCPIN/A

L68 10 SEA ABB=ON PLU=ON L66 NOT L5

L69 30 SEA ABB=ON PLU=ON L67 NOT L5

FILE 'REGISTRY' ENTERED AT 16:10:09 ON 22 MAR 2007

L70 0 SEA ABB=ON PLU=ON L19 AND DRUGU/LC

FILE 'EMBASE' ENTERED AT 16:11:02 ON 22 MAR 2007

L71 0 SEA ABB=ON PLU=ON OTTINGER ISABEL/AU

L72 4 SEA ABB=ON PLU=ON OTTINGER I?/AU  
D TRI 1-4

L73 0 SEA ABB=ON PLU=ON L72 AND L3

L74 0 SEA ABB=ON PLU=ON L71 OR L73

L75 94 SEA ABB=ON PLU=ON L22

L76 66 SEA ABB=ON PLU=ON L75 AND L28

L77 10 SEA ABB=ON PLU=ON L76 AND L31

SAV L77 POR258EMB/A

FILE 'BIOSIS' ENTERED AT 16:14:02 ON 22 MAR 2007

L78 61 SEA ABB=ON PLU=ON L23

L79 57 SEA ABB=ON PLU=ON L78 AND L28

D QUE

L80 12 SEA ABB=ON PLU=ON L79 AND L31

10/580258

SAV L80 POR258BIOS/A

L81 0 SEA ABB=ON PLU=ON OTTINGER ISABEL/AU  
L82 3 SEA ABB=ON PLU=ON OTTINGER I?/AU  
L83 0 SEA ABB=ON PLU=ON L82 AND L78  
L84 0 SEA ABB=ON PLU=ON L82 AND L28  
L85 0 SEA ABB=ON PLU=ON L82 AND L3  
L86 0 SEA ABB=ON PLU=ON L81 OR (L83 OR L84 OR L85)

FILE 'EMBASE' ENTERED AT 16:17:52 ON 22 MAR 2007

L87 0 SEA ABB=ON PLU=ON L71 OR (L73 OR L74)

FILE 'STNGUIDE' ENTERED AT 16:18:24 ON 22 MAR 2007

D QUE L5  
D QUE L86  
D QUE L87

FILE 'HCAPLUS' ENTERED AT 16:20:04 ON 22 MAR 2007

L88 5 DUP REM L5 L86 L87 (0 DUPLICATES REMOVED)  
ANSWERS '1-5' FROM FILE HCAPLUS  
D 1-5 IBIB ED ABS

FILE 'STNGUIDE' ENTERED AT 16:21:45 ON 22 MAR 2007

D QUE L68  
D QUE L69  
D QUE L80  
D QUE L77

FILE 'HCAPLUS, BIOSIS, EMBASE' ENTERED AT 16:24:33 ON 22 MAR 2007

L89 52 DUP REM L68 L69 L80 L77 (10 DUPLICATES REMOVED)  
ANSWERS '1-40' FROM FILE HCAPLUS  
ANSWERS '41-47' FROM FILE BIOSIS  
ANSWERS '48-52' FROM FILE EMBASE  
D L89 1-40 IBIB ED ABS HITSTR HITIND  
D L89 41-52 IBIB ED ABS HIT IND

L89 ANSWER 26 OF 52 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:20479 HCAPLUS Full-text  
 DOCUMENT NUMBER: 140:82221  
 TITLE: Pharmaceutical formulation comprising  
 non-peptide renin inhibitor  
 and surfactant  
 INVENTOR(S): Riedl, Jutta; Kannah, Satish; Dieterle, Walter  
 PATENT ASSIGNEE(S): Speedel Pharma A.-G., Switz.  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002466	A1	20040108	WO 2003-EP50266	2003 0625

<--  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
 MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC,  
 SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
 UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,  
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL,  
 PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003255527	A1	20040119	AU 2003-255527	2003 0625
---------------	----	----------	----------------	--------------

EP 1517682	A1	20050330	EP 2003-761592	2003 0625
------------	----	----------	----------------	--------------

<--  
 EP 1517682 B1 20061102  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
 MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ,  
 EE, HU, SK

US 2005147629	A1	20050707	US 2003-515817	2003 0625
---------------	----	----------	----------------	--------------

JP 2005533816	T	20051110	JP 2004-516786	2003 0625
---------------	---	----------	----------------	--------------

AT 344026	T	20061115	AT 2003-761592	2003 0625
-----------	---	----------	----------------	--------------

PRIORITY APPLN. INFO.: CH 2002-1124 A  
 2002  
 0628


<--  
 WO 2003-EP50266 W  
 2003  
 0625

AB Composition comprising (1) a non-peptide **renin inhibitor** which is poorly soluble to readily soluble in water and (2) at least one physiol. tolerated anionic **surfactant**, at least one physiol. tolerated amphoteric **surfactant**, at least one physiol. tolerated neutral **surfactant**, or a mixture of at least two of these **surfactants**, with the quantity of readily soluble **renin inhibitor** being at least 10% by weight, and the quantity of a poorly soluble **renin inhibitor** being at least 35% by weight, based on the composition. In oral administration forms, the composition exhibits increased bioavailability.

IT 25322-68-3  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (C8-C30 alkyl ether of; pharmaceutical formulation comprising non-peptide **renin inhibitor** and **surfactant**)

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl),  $\alpha$ -hydro- $\omega$ -hydroxy- (CA INDEX NAME)




IT 173334-57-1  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulation comprising non-peptide **renin inhibitor** and **surfactant**)

RN 173334-57-1 HCAPLUS

CN Benzeneoctanamide,  $\delta$ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- $\gamma$ -hydroxy-4-methoxy-3-(3-methoxypropoxy)- $\alpha,\zeta$ -bis(1-methylethyl)-, ( $\alpha$ S, $\gamma$ S, $\delta$ S,.z eta.S)- (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-195  
 ICS A61K031-425; A61K031-415; A61K038-55

CC 63-5 (Pharmaceuticals)

ST formulation nonpeptide **renin inhibitor**  
**surfactant**

IT Polyoxyalkylenes, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (C8-C30 alkyl ether of; pharmaceutical formulation comprising non-peptide **renin inhibitor** and **surfactant**)

IT Ethers, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (C8-C30-alkyl ether; pharmaceutical formulation comprising non-peptide **renin inhibitor** and **surfactant**)

IT Carboxylic acids, uses  
 RL: MOA (Modifier or additive use); USES (Uses)  
 (C8-C30; pharmaceutical formulation comprising non-peptide **renin inhibitor** and **surfactant**)

IT **Surfactants**  
(amphoteric; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Surfactants**  
(anionic; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Betaines**  
**Lecithins**  
**Phospholipids, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(as **surfactant**; pharmaceutical formulation comprising  
non-peptide **renin inhibitor and**  
**surfactant**)

IT **Drug delivery systems**  
(capsules; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Polymers, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(co-, polyethyleneoxy/polypropyleneoxy block; pharmaceutical  
formulation comprising non-peptide **renin**  
**inhibitor and surfactant**)

IT **Esters, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(diesters; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Carboxylic acids, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(esters, C8-C30; pharmaceutical formulation comprising  
non-peptide **renin inhibitor and**  
**surfactant**)

IT **Esters, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(monoester; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Surfactants**  
(neutral; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Drug delivery systems**  
(oral; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Acids, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(organic, as anionic **surfactant**; pharmaceutical  
formulation comprising non-peptide **renin**  
**inhibitor and surfactant**)

IT **Alcohols, uses**  
RL: MOA (Modifier or additive use); USES (Uses)  
(polyhydric, ethoxylated partial C8-C30 acid ester of;  
pharmaceutical formulation comprising non-peptide **renin**  
**inhibitor and surfactant**)

IT **Castor oil**  
RL: MOA (Modifier or additive use); USES (Uses)  
(polyoxyl; pharmaceutical formulation comprising non-peptide  
**renin inhibitor and surfactant**)

IT **Alkali metals, uses**  
**Alkaline earth metals**  
RL: MOA (Modifier or additive use); USES (Uses)  
(salt, as anionic **surfactant**; pharmaceutical  
formulation comprising non-peptide **renin**  
**inhibitor and surfactant**)

IT **Castor oil**  
RL: MOA (Modifier or additive use); USES (Uses)  
(sulfated, as **surfactant**; pharmaceutical formulation  
comprising non-peptide **renin inhibitor and**  
**surfactant**)

IT **Drug delivery systems**  
(tablets, coated, sugar coated; pharmaceutical formulation

comprising non-peptide renin inhibitor and surfactant)

IT Drug delivery systems  
(tablets; pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 25322-68-3  
RL: MOA (Modifier or additive use); USES (Uses)  
(C8-C30 alkyl ether of; pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 7732-18-5, Water, biological studies  
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(as non-peptide renin solvent; pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 151-21-3, Sodium lauryl sulfate, uses 577-11-7, Sodium dioctyl sulfosuccinate 1120-01-0, Sodium cetyl sulfate  
RL: MOA (Modifier or additive use); USES (Uses)  
(as surfactant; pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 9015-94-5, Renin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(non-peptide inhibitor; pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 12441-09-7, Sorbitan  
RL: MOA (Modifier or additive use); USES (Uses)  
(partial C8-C30 acid ester of; pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 56-81-5, Glycerol, uses  
RL: MOA (Modifier or additive use); USES (Uses)  
(pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)

IT 114469-22-6 126373-80-6 138742-43-5 173334-57-1  
188881-10-9 303042-86-6 304025-53-4  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)



L89 ANSWER 30 OF 52 HCAPLUS COPYRIGHT 2007 ACS on STN  
 .ACCESSION NUMBER: 2003:334884 HCAPLUS Full-text  
 DOCUMENT NUMBER: 138:343901  
 TITLE: Pharmaceutical compositions containing  
 AT1-receptor antagonists  
 INVENTOR(S): Buehlmayer, Peter; Webb, Randy Lee  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma  
 G.m.b.H.  
 SOURCE: PCT Int. Appl., 19 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035046	A2	20030501	WO 2002-EP11652	2002 1017
<--				
WO 2003035046	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2463758	A1	20030501	CA 2002-2463758	2002 1017
<--				
AU 2002363087	A1	20030506	AU 2002-363087	2002 1017
<--				
EP 1448190	A2	20040825	EP 2002-801896	2002 1017
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013357	A	20041026	BR 2002-13357	2002 1017
<--				
CN 1571668	A	20050126	CN 2002-820387	2002 1017
<--				
JP 2005509631	T	20050414	JP 2003-537613	2002 1017
<--				
US 2004266836	A1	20041230	US 2004-493040	2004 0507
<--				
PRIORITY APPLN. INFO.:			US 2001-330337P	P 2001 1018
<--				

&lt;--

ED Entered STN: 02 May 2003

AB The invention relates to a salt formed of at least one AT1-receptor antagonist having at least 1 acidic center and of at least 1 cardiovascular ingredient having at least one basic center that can be used for treating cardiovascular diseases and conditions, their prophylaxis or delay of progression. Thus, tablets contained a valsartan salt with another drug 500.0, lactose 500.0, potato starch 352.0, gelatin 8.0, talc 60.0, Mg stearate 10.0, and silica 20.0 g, and EtOH qs.


IT 173334-57-1 517875-94-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmaceutical compns. containing AT1-receptor antagonists)

RN 173334-57-1 HCAPLUS

CN Benzeneoctanamide,  $\delta$ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- $\gamma$ -hydroxy-4-methoxy-3-(3-methoxypropoxy)- $\alpha,\zeta$ -bis(1-methylethyl)-, ( $\alpha$ S, $\gamma$ S, $\delta$ S,.z eta.S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 517875-94-4 HCAPLUS


CN L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, compd. with ( $\alpha$ S, $\gamma$ S, $\delta$ S, $\zeta$ S)- $\delta$ -amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)- $\gamma$ -hydroxy-4-methoxy-3-(3-methoxypropoxy)- $\alpha,\zeta$ -bis(1-methylethyl)benzeneoctanamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 173334-57-1

CMF C30 H53 N3 O6

Absolute stereochemistry.



CM 2

CRN 137862-53-4

CMF C24 H29 N5 O3

Absolute stereochemistry.

